{"hands_on_practices": [{"introduction": "The first step in evaluating a patient with abnormal liver tests is to characterize the pattern of injury. This exercise introduces a quantitative method used in hepatology, the $R$ ratio, to objectively classify liver injury as cholestatic, hepatocellular, or mixed. By calculating this ratio for a hypothetical patient [@problem_id:4437470], you will practice applying a fundamental diagnostic principle that guides the entire subsequent workup.", "problem": "A patient with a long-standing history of ulcerative colitis presents with pruritus and fatigue. Magnetic resonance cholangiopancreatography suggests multifocal stricturing of the intrahepatic and extrahepatic bile ducts, raising concern for Primary Sclerosing Cholangitis (PSC). In hepatobiliary pathology, hepatocellular injury primarily elevates alanine aminotransferase (ALT), while cholestatic injury disproportionately elevates alkaline phosphatase (ALP). To compare enzyme elevations across laboratories with different reference ranges, clinicians normalize each enzyme to its Upper Limit of Normal (ULN) and compute a dimensionless ratio to classify the pattern of liver injury. Use the ratio defined by \n$$\nR \\equiv \\frac{\\left(\\text{ALT}/\\text{ALT}_{\\text{ULN}}\\right)}{\\left(\\text{ALP}/\\text{ALP}_{\\text{ULN}}\\right)}\n$$\nto quantify the pattern for this patient whose alanine aminotransferase (ALT) is $90 \\ \\text{U/L}$ with $\\text{ALT}_{\\text{ULN}}=40 \\ \\text{U/L}$ and whose alkaline phosphatase (ALP) is $520 \\ \\text{U/L}$ with $\\text{ALP}_{\\text{ULN}}=120 \\ \\text{U/L}$. Provide the exact value of $R$ as a simplified fraction. Report only the numeric value with no units.", "solution": "The problem is subjected to validation and is deemed valid. It is scientifically grounded in the principles of hepatobiliary pathology, well-posed with all necessary information provided, and objective in its formulation. No flaws were identified.\n\nThe objective is to calculate the dimensionless ratio $R$, which is used to classify the pattern of liver injury. The ratio is defined by the formula:\n$$\nR \\equiv \\frac{\\left(\\text{ALT}/\\text{ALT}_{\\text{ULN}}\\right)}{\\left(\\text{ALP}/\\text{ALP}_{\\text{ULN}}\\right)}\n$$\nwhere ALT is the alanine aminotransferase level, $\\text{ALT}_{\\text{ULN}}$ is the upper limit of normal for ALT, ALP is the alkaline phosphatase level, and $\\text{ALP}_{\\text{ULN}}$ is the upper limit of normal for ALP.\n\nThe given values for the patient are:\n- $\\text{ALT} = 90 \\ \\text{U/L}$\n- $\\text{ALT}_{\\text{ULN}} = 40 \\ \\text{U/L}$\n- $\\text{ALP} = 520 \\ \\text{U/L}$\n- $\\text{ALP}_{\\text{ULN}} = 120 \\ \\text{U/L}$\n\nFirst, we calculate the normalized ALT value, which is the ratio of the patient's ALT to the upper limit of normal for ALT:\n$$\n\\frac{\\text{ALT}}{\\text{ALT}_{\\text{ULN}}} = \\frac{90}{40}\n$$\nThis fraction can be simplified by dividing both the numerator and the denominator by their greatest common divisor, $10$:\n$$\n\\frac{90}{40} = \\frac{9}{4}\n$$\nNext, we calculate the normalized ALP value, which is the ratio of the patient's ALP to the upper limit of normal for ALP:\n$$\n\\frac{\\text{ALP}}{\\text{ALP}_{\\text{ULN}}} = \\frac{520}{120}\n$$\nThis fraction can be simplified. First, we divide by $10$:\n$$\n\\frac{520}{120} = \\frac{52}{12}\n$$\nThe greatest common divisor of $52$ and $12$ is $4$. Dividing the numerator and denominator by $4$:\n$$\n\\frac{52}{12} = \\frac{13}{3}\n$$\nNow, we substitute these simplified, normalized values back into the definition of the ratio $R$:\n$$\nR = \\frac{9/4}{13/3}\n$$\nTo divide by a fraction, we multiply by its reciprocal:\n$$\nR = \\frac{9}{4} \\times \\frac{3}{13}\n$$\nWe multiply the numerators together and the denominators together:\n$$\nR = \\frac{9 \\times 3}{4 \\times 13} = \\frac{27}{52}\n$$\nThe number $27$ has prime factors $3 \\times 3 \\times 3$, or $3^3$. The number $52$ has prime factors $2 \\times 2 \\times 13$, or $2^2 \\times 13$. Since there are no common prime factors between the numerator $27$ and the denominator $52$, the fraction $\\frac{27}{52}$ is in its simplest form. This is the exact value of $R$.\n\nClinically, a value of $R \\le 2$ suggests a cholestatic pattern of injury, $R \\ge 5$ suggests a hepatocellular pattern, and $2 < R < 5$ suggests a mixed pattern. The calculated value $R = \\frac{27}{52} \\approx 0.52$, which is less than $2$, is consistent with the cholestatic picture suggested by the patient's presentation and imaging findings concerning for Primary Sclerosing Cholangitis.", "answer": "$$\\boxed{\\frac{27}{52}}$$", "id": "4437470"}, {"introduction": "Once a cholestatic injury pattern is identified, a logical and efficient diagnostic pathway is crucial. This practice [@problem_id:4437343] challenges you to construct a stepwise algorithm for suspected PSC, simulating the clinical decision-making process. Mastering this involves balancing the diagnostic power of tests like Magnetic Resonance Cholangiopancreatography (MRCP) and Endoscopic Retrograde Cholangiopancreatography (ERCP) against their costs and risks, a core skill in modern medicine.", "problem": "A $35$-year-old individual presents with pruritus, fatigue, and a cholestatic pattern on liver function testing characterized by disproportionately elevated alkaline phosphatase and gamma-glutamyl transferase relative to transaminases (for example, alkaline phosphatase approximately $3\\times$ the Upper Limit of Normal (ULN)). The patient has no history of biliary surgery, reports no recent medication changes, and has a family history notable for inflammatory bowel disease. In the evaluation of suspected Primary Sclerosing Cholangitis (PSC), you are tasked with choosing a stepwise diagnostic algorithm that balances the principles of minimizing invasive procedures while maximizing diagnostic yield.\n\nFoundational facts and definitions to consider include:\n- Cholestasis is defined as impaired bile formation or flow, classically producing a biochemical pattern of elevated cholestatic enzymes with pruritus and fat-soluble vitamin deficiency.\n- Primary Sclerosing Cholangitis (PSC) is a chronic, immune-mediated fibroinflammatory disease of the intrahepatic and extrahepatic bile ducts that results in multifocal strictures and progressive cholestasis.\n- Non-invasive cholangiography with Magnetic Resonance Cholangiopancreatography (MRCP) is preferred for initial ductal mapping in suspected PSC.\n- Endoscopic Retrograde Cholangiopancreatography (ERCP) is primarily reserved for therapeutic interventions or targeted sampling when a dominant stricture or cholangiocarcinoma is suspected, due to its risk profile (for example, post-ERCP pancreatitis risk on the order of $3$–$10\\%$).\n- Liver biopsy is indicated when small-duct PSC is suspected (biochemical cholestasis with negative MRCP), or when overlap with autoimmune hepatitis is considered (for example, elevated immunoglobulins, autoantibodies, or interface hepatitis), rather than as a universal first-line test.\n- Exclusion of secondary causes of sclerosing cholangitis (for example, biliary obstruction from stones or malignancy, prior instrumentation, ischemic cholangiopathy, and Immunoglobulin G4 (IgG4)-related sclerosing cholangitis) is essential before labeling disease as primary.\n\nWhich option best represents a scientifically sound and efficient stepwise diagnostic algorithm for suspected PSC?\n\nA. $1$ Confirm cholestatic biochemical pattern; $2$ exclude secondary causes using history, medications, serologies (including IgG4), and cross-sectional imaging to rule out obstructive etiologies; $3$ perform Magnetic Resonance Cholangiopancreatography (MRCP) to identify multifocal strictures and beading; $4$ proceed to Endoscopic Retrograde Cholangiopancreatography (ERCP) with brush cytology only if MRCP suggests a dominant stricture or raises concern for cholangiocarcinoma; $5$ obtain liver biopsy if MRCP is non-diagnostic (to evaluate small-duct PSC) or if autoimmune hepatitis overlap is suspected.\n\nB. $1$ Perform Endoscopic Retrograde Cholangiopancreatography (ERCP) with brush cytology in all patients with cholestatic labs; $2$ use MRCP afterward to confirm ductal anatomy; $3$ exclude secondary causes after ERCP results; $4$ consider liver biopsy solely for staging fibrosis.\n\nC. $1$ Confirm cholestatic biochemical pattern; $2$ proceed directly to liver biopsy to look for periductal “onion-skin” fibrosis; $3$ perform MRCP subsequently to map ducts; $4$ exclude secondary causes at the end if MRCP is negative; $5$ use ERCP selectively for therapy.\n\nD. $1$ Confirm cholestatic biochemical pattern and perform MRCP; $2$ conduct ERCP in all cases regardless of MRCP findings to obtain brush cytology; $3$ exclude secondary causes only if ERCP is negative; $4$ avoid liver biopsy because imaging is definitive.\n\nE. $1$ Confirm cholestatic biochemical pattern; $2$ exclude secondary causes; $3$ perform transjugular liver biopsy in all suspected PSC cases to establish diagnosis and stage disease; $4$ reserve MRCP for cases with ambiguous histology; $5$ use ERCP opportunistically to sample any visible stricture regardless of MRCP findings.", "solution": "The user has presented a clinical problem requiring the selection of an optimal diagnostic algorithm for suspected Primary Sclerosing Cholangitis (PSC). The task necessitates a critical validation of the problem statement, followed by a systematic derivation of the solution based on provided principles.\n\n**Problem Validation**\n\n**Step 1: Extract Givens**\n-   **Patient Profile:** A $35$-year-old individual.\n-   **Symptoms:** Pruritus, fatigue.\n-   **Biochemistry:** Cholestatic pattern on liver function testing; alkaline phosphatase approximately $3\\times$ the Upper Limit of Normal (ULN); gamma-glutamyl transferase disproportionately elevated relative to transaminases.\n-   **History:** No biliary surgery, no recent medication changes, family history of inflammatory bowel disease.\n-   **Diagnostic Goal:** To choose a stepwise algorithm for suspected Primary Sclerosing Cholangitis (PSC) that balances minimizing invasive procedures with maximizing diagnostic yield.\n-   **Foundational Facts:**\n    1.  Cholestasis is impaired bile flow with a characteristic biochemical pattern.\n    2.  PSC is a chronic, immune-mediated disease causing multifocal bile duct strictures.\n    3.  Magnetic Resonance Cholangiopancreatography (MRCP) is the preferred non-invasive method for initial ductal mapping.\n    4.  Endoscopic Retrograde Cholangiopancreatography (ERCP) is a higher-risk procedure (e.g., $3$–$10\\%$ post-ERCP pancreatitis risk) reserved for therapeutic intervention or targeted sampling of dominant strictures or suspected malignancy.\n    5.  Liver biopsy is indicated for suspected small-duct PSC (when MRCP is negative despite clinical suspicion) or suspected overlap with autoimmune hepatitis, not as a universal first-line test.\n    6.  Exclusion of secondary causes of sclerosing cholangitis (e.g., stones, malignancy, prior instrumentation, ischemic cholangiopathy, Immunoglobulin G4 ($IgG4$)-related disease) is an essential prerequisite for a diagnosis of PSC.\n\n**Step 2: Validate Using Extracted Givens**\n-   **Scientific Grounding:** The problem is scientifically sound. The clinical presentation is classic for PSC. The provided definitions and principles regarding the roles of MRCP, ERCP, liver biopsy, and the importance of excluding secondary causes are consistent with current, evidence-based clinical practice guidelines in hepatology. The risk profile for ERCP is stated realistically.\n-   **Well-Posedness:** The problem is well-posed. It asks for the \"best\" algorithm based on a clear optimization principle: balancing diagnostic yield against procedural risk (invasiveness). The provided foundational facts serve as constraints that guide the construction of a single, logical, and optimal diagnostic sequence.\n-   **Objectivity:** The problem is stated in objective, clinical language, free from bias or subjective claims. The \"foundational facts\" are presented as established principles, which they are.\n\n**Step 3: Verdict and Action**\nThe problem statement is **valid**. It is scientifically grounded, well-posed, objective, and contains sufficient information to derive a correct solution. The process will now proceed to the solution derivation.\n\n**Solution Derivation**\n\nBased on the provided foundational facts and the governing principle of medical diagnostics (proceed from least invasive to most invasive), a logical and efficient algorithm for suspected PSC can be constructed.\n\n1.  **Confirmation of Cholestasis:** The initial step must be to confirm the presence of a cholestatic liver injury biochemically. The patient's presentation with elevated alkaline phosphatase ($~3\\times$ ULN) and GGT fulfills this.\n\n2.  **Exclusion of Secondary Causes:** Before diagnosing a \"primary\" idiopathic condition, it is imperative to rule out other known causes. The problem statement lists these as obstruction (stones, malignancy), iatrogenic causes (instrumentation), ischemic injury, and mimics like $IgG4$-related sclerosing cholangitis. This requires a thorough history, medication review, basic imaging (such as an abdominal ultrasound, a type of cross-sectional imaging), and serological tests, including serum $IgG4$.\n\n3.  **Non-invasive Cholangiography:** Once macroscopic obstruction and other secondary causes are reasonably ruled out, the anato-pathologic basis for cholestasis—the state of the biliary tree—must be assessed. The provided facts explicitly state that \"MRCP is preferred for initial ductal mapping.\" This non-invasive test can visualize the characteristic multifocal strictures and segmental dilatations (\"beading\") of large-duct PSC. A characteristic MRCP in this clinical context is sufficient for diagnosis.\n\n4.  **Selective Use of Invasive Procedures:** Invasive tests are reserved for situations where non-invasive testing is inconclusive or when intervention is required.\n    -   **ERCP:** As stated, ERCP is indicated \"when a dominant stricture or cholangiocarcinoma is suspected.\" This is typically a finding on MRCP that requires further evaluation (e.g., brush cytology, biopsy) or therapeutic intervention (e.g., dilation, stenting). Its routine use is precluded by its significant risk profile.\n    -   **Liver Biopsy:** Its role is not for primary diagnosis when MRCP is positive. The stated indications are for suspected \"small-duct PSC\" (i.e., cholestatic biochemistry and consistent histology, but a normal MRCP) or when there is suspicion of an \"overlap with autoimmune hepatitis.\"\n\nThis derived algorithm serves as the standard against which the options will be evaluated.\n\n**Option-by-Option Analysis**\n\n**A. $1$ Confirm cholestatic biochemical pattern; $2$ exclude secondary causes using history, medications, serologies (including IgG4), and cross-sectional imaging to rule out obstructive etiologies; $3$ perform Magnetic Resonance Cholangiopancreatography (MRCP) to identify multifocal strictures and beading; $4$ proceed to Endoscopic Retrograde Cholangiopancreatography (ERCP) with brush cytology only if MRCP suggests a dominant stricture or raises concern for cholangiocarcinoma; $5$ obtain liver biopsy if MRCP is non-diagnostic (to evaluate small-duct PSC) or if autoimmune hepatitis overlap is suspected.**\nThis option follows the derived algorithm precisely. It begins with confirming the biochemical abnormality, proceeds to the crucial step of excluding secondary causes, uses the correct primary non-invasive imaging modality (MRCP), and reserves the higher-risk, invasive procedures (ERCP and biopsy) for their specific, appropriate indications as outlined in the foundational facts. This represents a safe, logical, and high-yield diagnostic pathway.\n**Verdict: Correct**\n\n**B. $1$ Perform Endoscopic Retrograde Cholangiopancreatography (ERCP) with brush cytology in all patients with cholestatic labs; $2$ use MRCP afterward to confirm ductal anatomy; $3$ exclude secondary causes after ERCP results; $4$ consider liver biopsy solely for staging fibrosis.**\nThis option is fundamentally flawed. It begins with a high-risk invasive procedure (ERCP) as a screening tool, which directly violates the foundational principles and standard of care. Using MRCP *after* ERCP is illogical. Excluding secondary causes late in the process is incorrect. The stated role for liver biopsy is also incomplete.\n**Verdict: Incorrect**\n\n**C. $1$ Confirm cholestatic biochemical pattern; $2$ proceed directly to liver biopsy to look for periductal “onion-skin” fibrosis; $3$ perform MRCP subsequently to map ducts; $4$ exclude secondary causes at the end if MRCP is negative; $5$ use ERCP selectively for therapy.**\nThis option incorrectly prioritizes an invasive liver biopsy over non-invasive cholangiography. The foundational facts explicitly state that biopsy is not a universal first-line test. The \"onion-skin\" finding is specific but not sensitive (i.e., not always present). The proper sequence is MRCP first, then biopsy only if indicated. Placing the exclusion of secondary causes at the end is a critical error.\n**Verdict: Incorrect**\n\n**D. $1$ Confirm cholestatic biochemical pattern and perform MRCP; $2$ conduct ERCP in all cases regardless of MRCP findings to obtain brush cytology; $3$ exclude secondary causes only if ERCP is negative; $4$ avoid liver biopsy because imaging is definitive.**\nThis option contains multiple errors. It advocates for routine ERCP, which is contraindicated by the risk profile. It incorrectly defers the exclusion of secondary causes. Furthermore, it falsely claims that imaging is always definitive and that biopsy should be avoided, which contradicts the stated indication for biopsy in suspected small-duct PSC (where imaging is by definition non-diagnostic).\n**Verdict: Incorrect**\n\n**E. $1$ Confirm cholestatic biochemical pattern; $2$ exclude secondary causes; $3$ perform transjugular liver biopsy in all suspected PSC cases to establish diagnosis and stage disease; $4$ reserve MRCP for cases with ambiguous histology; $5$ use ERCP opportunistically to sample any visible stricture regardless of MRCP findings.**\nThis option, similar to C, incorrectly proposes routine liver biopsy as a primary diagnostic step for all patients. It inverts the roles of MRCP and biopsy, relegating MRCP to a secondary test. The term \"opportunistically\" for ERCP is vague and does not reflect an indication-based, risk-managed approach.\n**Verdict: Incorrect**", "answer": "$$\\boxed{A}$$", "id": "4437343"}, {"introduction": "Making a diagnosis of sclerosing cholangitis on imaging is not the final step; it is critical to distinguish Primary Sclerosing Cholangitis (PSC) from its mimics. This problem [@problem_id:4437466] presents a classic scenario of differentiating PSC from IgG4-related sclerosing cholangitis. You will need to synthesize data from multiple domains—serology, imaging, histology, and response to therapy—to make the correct distinction, honing your skills in complex pattern recognition.", "problem": "A pathology laboratory is asked to help differentiate immune-mediated fibroinflammatory disease of the bile ducts from classic cholestatic scarring disease. The chief pathologist reminds the team that diagnostic classification in immunopathology proceeds by integrating fundamental domains: serology (immunoglobulin subclass patterns), imaging morphology (stricture architecture and distribution), histologic patterns (type and arrangement of fibrosis and inflammatory infiltrate), multi-organ involvement (systemic versus organ-limited disease), and therapeutic response (particularly to glucocorticoids). The laboratory’s reference interval for Immunoglobulin G subclass 4 (IgG4) is $<135$ mg/dL. Magnetic Resonance Cholangiopancreatography (MRCP) reports define “long, smooth segmental strictures” as continuous narrowing $>2$ cm with regular walls, and “beaded multifocal strictures” as alternating short narrowings and dilations in multiple intra- or extrahepatic segments. Histology reports describe “storiform fibrosis” as cartwheel-like whorled collagen with a dense lymphoplasmacytic infiltrate, and enumerate IgG4-positive plasma cells per high-power field (HPF). In immune-mediated disease, a sustained and substantial biochemical and imaging improvement after systemic glucocorticoids is interpreted as a positive therapeutic response.\n\nFour patients present with cholestatic symptoms and bile duct stricturing. Based on the integrated domains above, which profile most strongly supports Immunoglobulin G subclass 4-related sclerosing cholangitis (IgG4-SC) rather than primary sclerosing cholangitis (PSC)?\n\nA. A $48$-year-old man with pruritus and cholestatic enzymes; MRCP shows a single long, smooth $3$ cm segmental stricture of the common hepatic duct; serum IgG4 is $380$ mg/dL (reference $<135$); pancreatic imaging shows diffuse enlargement with a halo; submandibular glands are enlarged; liver biopsy reveals storiform fibrosis, obliterative phlebitis, and dense IgG4-positive plasma cells with an IgG4$^{+}$/IgG$^{+}$ ratio of $45\\%$ and $>50$ IgG4-positive cells/HPF; after oral prednisone, cholestatic enzymes and stricture caliber improve markedly within $4$ weeks.\n\nB. A $29$-year-old man with ulcerative colitis (UC); MRCP demonstrates beaded multifocal short intra- and extrahepatic strictures; perinuclear Antineutrophil Cytoplasmic Antibody (p-ANCA) is positive; serum IgG4 is $110$ mg/dL; liver biopsy shows concentric periductal “onion-skin” fibrosis; there is no meaningful biochemical or imaging improvement after a $6$-week steroid trial.\n\nC. A $42$-year-old woman with cholestatic enzymes; MRCP shows multifocal, irregular short strictures and segmental dilations; serum IgG4 is $170$ mg/dL; no pancreatic, salivary gland, or retroperitoneal involvement is detected; liver biopsy shows periductal fibrosis without storiform architecture and scant plasma cells; a $4$-week course of steroids yields only minimal improvement.\n\nD. A $55$-year-old man with pruritus; MRCP reveals a long, smooth $2.5$ cm stricture of the proximal common bile duct; serum IgG4 is $250$ mg/dL; no pancreatic, salivary, or retroperitoneal lesions are identified; biopsy shows nonspecific portal fibrosis without obliterative phlebitis and with $<10$ IgG4-positive plasma cells/HPF; there is no significant response after a $6$-week prednisone course.\n\nChoose the single best option.", "solution": "The problem requires identifying the patient profile that most strongly supports a diagnosis of Immunoglobulin G subclass 4-related sclerosing cholangitis (IgG4-SC) over primary sclerosing cholangitis (PSC) by integrating findings from multiple diagnostic domains. The correct approach is to evaluate each option against the established features of IgG4-SC and PSC as described in the problem's premise.\n\n**Analysis of Diagnostic Domains for IgG4-SC vs. PSC:**\n\n*   **Serology:** IgG4-SC is associated with markedly elevated serum IgG4 levels. PSC typically has normal IgG4 levels.\n*   **Imaging (MRCP):** IgG4-SC often presents with long, smooth, continuous strictures, particularly in the distal bile duct. PSC characteristically shows multifocal, short, \"beaded\" strictures.\n*   **Multi-organ Involvement:** IgG4-SC is a systemic disease, frequently involving other organs such as the pancreas (autoimmune pancreatitis), salivary glands, or retroperitoneum. PSC is primarily a biliary disease, though strongly associated with inflammatory bowel disease (IBD).\n*   **Histology:** IgG4-SC is defined by a dense lymphoplasmacytic infiltrate rich in IgG4-positive plasma cells ($>10-50$/HPF depending on criteria), storiform (\"cartwheel\") fibrosis, and obliterative phlebitis. PSC's hallmark is \"onion-skin\" concentric periductal fibrosis.\n*   **Therapeutic Response:** IgG4-SC typically shows a rapid and dramatic improvement in both biochemical markers and imaging findings in response to glucocorticoid (steroid) therapy. PSC is not responsive to steroids.\n\n**Option-by-Option Evaluation:**\n\n*   **A:** This patient's profile aligns perfectly with the classic presentation of IgG4-SC. It includes:\n    *   **Serology:** Markedly elevated IgG4 ($380$ mg/dL).\n    *   **Imaging:** A long, smooth segmental stricture.\n    *   **Multi-organ Involvement:** Pancreatic and submandibular gland enlargement.\n    *   **Histology:** Storiform fibrosis, obliterative phlebitis, and a dense IgG4-positive infiltrate ($>50$ cells/HPF with a high ratio), all of which are pathognomonic.\n    *   **Therapeutic Response:** A marked and rapid improvement with prednisone.\n    Every single domain strongly points to IgG4-SC.\n\n*   **B:** This patient's profile is a textbook example of classic PSC. It includes association with ulcerative colitis, \"beaded\" multifocal strictures on MRCP, normal IgG4, characteristic \"onion-skin\" fibrosis on biopsy, and a lack of response to steroids.\n\n*   **C:** This profile is ambiguous. While the serum IgG4 is elevated ($170$ mg/dL), it is only modestly so. The imaging findings (\"multifocal, irregular short strictures\") are more typical of PSC. There is no other organ involvement, the histology is non-specific, and the response to steroids is minimal. This does not strongly support IgG4-SC.\n\n*   **D:** This profile also has mixed features. The elevated IgG4 and long stricture are suggestive of IgG4-SC. However, the lack of other organ involvement, the non-specific histology with very few IgG4-positive cells, and the absence of a therapeutic response all argue strongly against IgG4-SC. A lack of steroid response in the face of a dominant stricture and elevated IgG4 would raise suspicion for cholangiocarcinoma rather than IgG4-SC.\n\n**Conclusion:**\n\nOption A is the only choice where all five diagnostic domains—serology, imaging, systemic involvement, histology, and therapeutic response—coherently and strongly support the diagnosis of IgG4-related sclerosing cholangitis. The other options either represent classic PSC or have ambiguous/contradictory features that make the diagnosis of IgG4-SC unlikely or weak. Therefore, profile A is the most compelling case.", "answer": "$$\\boxed{A}$$", "id": "4437466"}]}